Agios Pharmaceuticals Inc (AGIO)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

88 SIDNEY STREET CAMBRIDGE, MA 02139

Agios Pharmaceuticals Inc is engaged in the development of medicines to treat the cancer metaboli® and inborn errors of metaboli® which are a subset of orphan genetic metabolic diseases.

Data based on most recent fiscal year report
Market Cap4.119 Billion Shares Outstanding55.71 Million Avg Volume821.914 Thousand
1-Yr BETA vs S&P TR1.737 Current Ratio4.69 Quick Ratio4.69
View SEC Filings from AGIO instead.
Q2 2019 All Institutions Hedge Funds 1
To trade AGIO now:
Filers who had this stock in their top 10: 1 0 (0.0%)
13F Filers holding this stock: 181 28 (2.89%)
Aggregate 13F shares on 06/30/2019: 59.519 Million 4.02 Million
Aggregate 13F shares on 03/31/2019: 59.142 Million 3.233 Million
Percent change: 0.64% 24.36%
Funds creating new positions: 26 13
Funds Adding to an existing position: 67 9
Funds closing out their position: 36 12
Funds reducing their position: 60 3
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding AGIO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

NELSEN ROBERT

  • Director
  • 10% Owner
444,444 2019-10-10 0

CLANCY PAUL J

  • Director
2,226 2019-09-30 1

FOUSE JACQUALYN A

  • Director
2,831 2019-09-30 2

CLARK IAN T

  • Director
1,302 2019-09-25 1

MARAGANORE JOHN CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
193,126 2019-08-06 2

BOWDEN CHRISTOPHER

  • Director
0 2019-06-19 5

KARSEN PERRY A

  • Director
0 2019-06-13 0

HIGGONS JOHN DUNCAN

  • Director
0 2019-06-12 0

HIRSCH ANDREW

  • Director
0 2019-06-12 3

BILLER SCOTT CHIEF SCIENTIFIC OFFICER

  • Officer
86,788 2019-06-11 8

SCADDEN DAVID

  • Director
0 2019-06-07 1

SCHENKEIN DAVID P

  • Director
5,176 2019-06-06 2

HOERTER STEVEN L.

  • Director
0 2019-06-06 3

STARR KEVIN P

0 2019-06-05 0

HO MAYKIN

  • Director
6,555 2019-06-05 1

TESSIER-LAVIGNE MARC

  • Director
0 2019-05-30 0

COLE DOUGLAS G.

  • Director
0 2019-05-30 0

FOSTER-CHEEK KAYE I

  • Director
3,600 2019-05-29 1

ALENSON CARMAN PRINCIPAL ACCOUNTING OFFICER

  • Officer
2,796 2019-02-21 1

GODDARD GLENN EVP, CHIEF FINANCIAL OFFICER

  • Officer
0 2018-12-18 0

CELGENE CORP /DE/

CELGENE SWITZERLAND LLC

CELGENE ALPINE INVESTMENT CO., LLC

CELGENE EUROPEAN INVESTMENT CO LLC

  • 10% Owner
6,718,433 2018-01-23 0

CANTLEY LEWIS CLAYTON JR.

  • Director
200,596 2017-12-06 0

ARCH VENTURE FUND VII LP

ARCH VENTURE PARTNERS VII, L.P.

ARCH VENTURE PARTNERS VII, LLC

CRANDELL KEITH

BYBEE CLINTON

  • 10% Owner
4,637,137 2016-07-06 0

FLAGSHIP VENTURES FUND 2007, L.P.

FLAGSHIP VENTURES 2007 GENERAL PARTNER LLC

AFEYAN NOUBAR

KANIA EDWIN M JR

  • Director
  • 10% Owner
31,115 2016-06-21 0

THIRD ROCK VENTURES LP

THIRD ROCK VENTURES GP, L.P.

TRV GP, LLC

  • 10% Owner
No longer subject to file 2015-04-07 0

CELGENE EUROPEAN INVESTMENT CO LLC

  • 10% Owner
5,242,704 2014-12-16 0

CELGENE EUROPEAN INVESTMENT CO LLC

CELGENE CORP /DE/

CELGENE ALPINE INVESTMENT CO., LLC

  • 10% Owner
5,014,059 2014-04-29 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions
Click here to report any possible errors with this stock listing.

Elevate your investments